- Home
- ASGI vs VALN Comparison
ASGI vs VALN Comparison
Compare ASGI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASGI
- VALN
- Stock Information
- Founded
- ASGI 2019
- VALN 2012
- Country
- ASGI United States
- VALN France
- Employees
- ASGI N/A
- VALN N/A
- Industry
- ASGI Investment Managers
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASGI Finance
- VALN Health Care
- Exchange
- ASGI Nasdaq
- VALN Nasdaq
- Market Cap
- ASGI 501.0M
- VALN 510.7M
- IPO Year
- ASGI N/A
- VALN 2021
- Fundamental
- Price
- ASGI $19.03
- VALN $6.41
- Analyst Decision
- ASGI
- VALN Strong Buy
- Analyst Count
- ASGI 0
- VALN 3
- Target Price
- ASGI N/A
- VALN $15.33
- AVG Volume (30 Days)
- ASGI 83.3K
- VALN 12.4K
- Earning Date
- ASGI 01-01-0001
- VALN 05-07-2025
- Dividend Yield
- ASGI 8.76%
- VALN N/A
- EPS Growth
- ASGI N/A
- VALN N/A
- EPS
- ASGI N/A
- VALN N/A
- Revenue
- ASGI N/A
- VALN $201,099,222.00
- Revenue This Year
- ASGI N/A
- VALN $17.98
- Revenue Next Year
- ASGI N/A
- VALN $26.61
- P/E Ratio
- ASGI N/A
- VALN N/A
- Revenue Growth
- ASGI N/A
- VALN 21.64
- 52 Week Low
- ASGI $14.96
- VALN $3.62
- 52 Week High
- ASGI $18.55
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- ASGI 61.67
- VALN 45.78
- Support Level
- ASGI $18.87
- VALN $6.18
- Resistance Level
- ASGI $19.25
- VALN $6.55
- Average True Range (ATR)
- ASGI 0.22
- VALN 0.32
- MACD
- ASGI 0.01
- VALN -0.02
- Stochastic Oscillator
- ASGI 70.27
- VALN 23.30
About ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest
abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.